Boiron (BOI.PA) Stock Price
Boiron Price
Over the last 19 years Boiron grew revenue by 1.2% annually, reaching 501.11 M EUR. Earnings per share have grown at 7.5% per year over the last 19 years. For Boiron, the net margin of 6.5% is broadly stable versus 6.3% a few years ago. At today's price the dividend yield works out to roughly 6.12%. The payout ratio is around 65% of earnings. The dividend has grown at 6.4% per year over the past 19 years. The consensus 12-month price target for Boiron is 40.43 EUR, about 106.3% above where the stock trades today. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.
Boiron stock price
Boiron business model & stock analysis
Frequently asked questions about Boiron
The business model of Boiron SA is focused on the development, production, and distribution of homeopathic products. As a leading pharmaceutical company, Boiron specializes in providing natural and alternative medicines to customers worldwide. The company's core values include a commitment to research, innovation, and quality. Boiron's extensive product portfolio ranges from single homeopathic medicines to complex remedies, ensuring a wide variety of options for various health conditions. With a strong emphasis on patient well-being, Boiron SA aims to promote the benefits of homeopathy and improve the quality of life for individuals seeking alternative healthcare solutions.
Boiron SA is primarily active in the healthcare industry.
The main competitors of Boiron SA in the market are Hyland's, Nelsons, and Weleda.
Boiron SA is a renowned global pharmaceutical company based in France. Founded in 1932 by Jean and Henri Boiron, the company specializes in manufacturing and distributing homeopathic medicines. With years of dedication and expertise, Boiron SA has become a trusted name in the pharmaceutical industry. The company's success can be attributed to its commitment to quality and innovation. Boiron SA continues to expand its product range and has a strong presence in over 50 countries worldwide. With a rich history and unwavering dedication to homeopathy, Boiron SA remains a leading player in the global healthcare market.
Boiron SA, a prominent stock company, has achieved several significant milestones. Over its history, the company has made noteworthy accomplishments in the pharmaceutical industry. Boiron SA has successfully expanded its presence across various international markets, enabling global recognition and revenue growth. Additionally, the company has consistently delivered cutting-edge healthcare solutions and innovative products, establishing itself as a leader in the industry. Boiron SA's commitment to research and development has resulted in breakthrough treatments and improved patient outcomes. With a strong dedication to excellence, Boiron SA continues to drive advancements in the pharmaceutical sector, solidifying its position as a trusted and successful stock investment opportunity.
Boiron SA is primarily present in several countries and regions across the globe. The company has a significant presence in Europe, with a strong focus on its home market in France. Boiron SA also operates in various other European countries, including Germany, Italy, Spain, and the United Kingdom. Additionally, the company has established a presence in North America, particularly in the United States and Canada. Boiron SA's presence extends further to countries in Asia, such as China and Japan. With a global reach, Boiron SA serves customers and markets in multiple countries and regions, solidifying its position as a leading company in the pharmaceutical industry.
Boiron SA represents a set of core values and a strong corporate philosophy. With a focus on customer satisfaction and healthcare excellence, Boiron SA aims to provide high-quality and effective homeopathic medicines. The company is committed to promoting natural health solutions and sustainability, ensuring the well-being of individuals and the environment. Boiron SA's dedication to research, innovation, and expertise drives their mission of improving people's lives through safe and trusted homeopathic remedies. Known for their commitment to ethics and responsibility, Boiron SA strives to be a leader in the global homeopathy market, bringing holistic wellness to individuals worldwide.
Analysts currently set an average price target of 40.43 EUR for the Boiron stock (median: 40.43 EUR), implying +106.3 % versus the latest price. The consensus is based on 5 analyst ratings.
5 analysts currently rate the Boiron stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Boiron to generate revenue of 522.30 M EUR and earnings per share of 2.03 EUR.
The Boiron share (BOI.PA) is listed on 7 stock exchanges, including: London (0DTF.L), Frankfurt (BON.F), München (BON.MU), Düsseldorf (BON.DU), Paris (BOI.PA).
Boiron SA is a leading manufacturer of homeopathic medicines, founded in 1932 and based in Lyon, France. The company consists of three business areas - healthcare, sustainability, and research & development.
The expected revenue of Boiron is 522.30 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Boiron is 35.77 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Boiron is currently 9.67. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Boiron stock.
The price-to-sales ratio (P/S) of Boiron is currently 0.66. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Boiron stock.
The Eulerpool Quality Score for Boiron is 2/10.
The ISIN of Boiron is FR0000061129. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Boiron is 873532. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Boiron is BOI.PA. The ticker symbol is used to trade Boiron shares on the stock exchange.
Over the past 12 months, Boiron paid a dividend of 1.20 EUR . This corresponds to a dividend yield of about 6.12 %. For the coming 12 months, Boiron is expected to pay a dividend of 1.45 EUR.
The current dividend yield of Boiron is 6.12 %.
Boiron pays a dividend, distributed in the months of October, June.
Boiron paid dividends every year for the past 36 years.
For the upcoming 12 months, dividends amounting to 1.45 EUR are expected. This corresponds to a dividend yield of 7.39 %.
Boiron is assigned to the 'Health' sector.
In the year 2025, Boiron distributed 1.2 EUR as dividends.
The dividends of Boiron are distributed in EUR.
Boiron stock
Boiron Peer Group
Boiron Ticker
Boiron FIGI
All fundamentals and in-depth analysis of Boiron
Our stock analysis for Boiron stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Boiron. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.